Lund, Sweden, 15:00 CET, 5 September 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, invite journalists, analysts and investors to its Capital Markets Days in Stockholm and London.
Speakers at the events from BONESUPPORT’s Executive Management Team will be Emil Billbäck CEO, Björn Westberg CFO, Dr Michael Diefenbeck, Head of R&D, Medical and Clinical Affairs and Patrick O’ Donnell, Executive Vice President Commercial Operations North America. The Capital Market Days will also include a presentation on CERAMENT in clinical application in Stockholm by Anders Jönsson, Senior Consultant Orthopedic Surgeon at Sahlgrenska University Hospital and in London by Professor Venu Kavarthapu, Senior Consultant Surgeon at Kings College Hospital, London.
The agenda* is as follows:
|
Sep 19 Stockholm |
Sep 20 London |
|
|
09.00 |
09.30 |
Introduction |
|
|
|
The CERAMENT platform |
|
|
|
CERAMENT in clinical application |
|
|
|
Market Opportunity |
|
|
|
Q&A |
|
10.05-10.20 |
10.35-10.50 |
Coffee break |
|
10.20 |
10.50 |
Strategy |
|
|
|
Product innovation |
|
|
|
Generating clinical data |
|
|
|
Our HEOR activities |
|
|
|
EUROW Commercial platform |
|
|
|
US Commercial platform |
|
11.30 |
12.00 |
Financial overview |
|
|
|
Wrap up |
|
|
|
Q&A |
- Subject to change
The Capital Markets Days will be held in English. Further information will be available on the Company’s website prior to the event. Please register by using this link https://www.bonesupport.com/en-eu/calendar/ by 14 September. The event in Stockholm will be led by Charlotte Stjerngren. The event will be webcasted. More information will be available via the same link prior to the webcast.
About BONESUPPORT™
BONESUPPORT is an innovative commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis), ortho-oncology, foot and ankle, and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
In addition, BONESUPPORT is looking to expand its product offering in the US and has entered into a strategic agreement with MTF Biologics and Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only.
CERAMENT V: Not available in the United States.
BONESUPPORT™ and CERAMENT® are registered trademarks.
For more information contact:
BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir
+44 (0)20 7282 1022
The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on 5 September 2018.